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Vaginal microbicides that reduce or eliminate the risk of HIV-1 sexual transmission must do so safely without adversely aﬀecting
the integrity of the cervicovaginal epithelium. The present studies were performed to assess the safety of the biguanide-based
antiviral compound NB325 in a formulation suitable for topical application. Experiments were performed using a mouse model
of cervicovaginal microbicide application, which was previously shown to be predictive of topical agent toxicity revealed in
microbicideclinicaltrials.MicewereexposedvaginallytounformulatedNB325orNB325formulatedinthehydroxyethylcellulose
“universal placebo.” Following exposures to formulated 1% NB325 for 10min to 24h, the vaginal and cervical epithelia were
generally intact, although some areas of minimal vaginal epithelial damage were noted. Although formulated NB325 appeared
generally safe for application in these studies, the low but observable level of toxicity suggests the need for improvements in the
compound and/or formulation.
1.Introduction
Despite eﬀorts to combat human immunodeﬁciency virus
type 1 (HIV-1) infection through the use of highly eﬀective
combination therapies, HIV-1 has continued to spread. By
2009, the number of individuals living with HIV-1 reached
a staggering 33.3 million people worldwide [1]. Since the
beginning of the epidemic almost 30 years ago, the propor-
tion of HIV-1-infected women in this population has risen
steadily, stabilizing recently at approximately 52%. Women
in sub-Saharan Africa are at particular risk, as evidenced
by the greater prevalence of women (approximately 60%)
in the HIV-1-infected population and the predominant
transmission of HIV-1 through unprotected heterosexual
intercourse [1]. This route of transmission continues to
prevail because eﬀective methods of prevention, such as the
male condom, are inconsistently used due to various social,
cultural, economic, and religious issues.
Toaddressthecriticalneedforaneﬀectiveandacceptable
means to check the spread of HIV-1, numerous investigators
around the world are working toward the development of
microbicides, which are formulated chemical entities that
can be applied vaginally or rectally to prevent or eliminate
HIV-1 transmission [2–5]. The ideal microbicide would
be highly active against HIV-1 but may also have activity
against other sexually transmitted disease pathogens. For
optimal acceptability, a formulated microbicide should be
colorless, tasteless, and odorless to allow for discretion in2 Journal of Biomedicine and Biotechnology
its use and should also be inexpensive and easy to apply [3,
6]. Importantly, a topical formulation containing an active
pharmaceutical ingredient (API) must be safe for topical
vaginal and/or rectal use, causing no adverse changes in
epithelial barrier functions and no local inﬂammation that
might increase susceptibility to HIV-1 infection. Although a
microbicideisnotyetavailableforworldwideuse,thereverse
transcriptase inhibitor tenofovir was recently shown to be a
safe, eﬀective microbicide API in women at risk for HIV-1
infection [7].
Our eﬀorts have been directed toward the development
of biguanide-based compounds for use in microbicides
eﬀective against HIV-1. Polybiguanides (PBGs) are polyca-
tionic in nature and are made up of repeating biguanide
units that are separated by hydrocarbon linkers of varying
lengths [8]. PBGs have been used safely for more than 30
years for vaginal disinfection (chlorhexidine digluconate),
antimalarial therapy (proguanil), and treatment of type
2 diabetes (metformin). They are also used as the active
ingredient in contact lens disinfectants, mouth rinses, and
wound disinfectants [8–16].
Our studies of PBG compounds as microbicide APIs
have encompassed activity, safety, and mechanism of action.
Early experiments with a small number of PBGs indicated
that polyethylene hexamethylene biguanide (PEHMB) was
an eﬀective HIV-1 inhibitor characterized by minimal in
vitro cytotoxicity [8]. Expanded studies of structure-activity
relationships among diﬀerent PBG compounds demon-
strated clear relationships between molecule structure and
biological activity [17]. Furthermore, the results of these
studies suggested that PEHMB acted against X4 and R5
strains of HIV-1 as a viral entry inhibitor by interacting
with the host cell rather than the virus [17]. In a series
of experiments focused on conﬁrming this mechanism of
action against HIV-1, PEHMB (later designated NB325) was
shown to inhibit HIV-1 infection by interacting speciﬁcally
with the second extracellular loop of CXCR4, which serves
as the HIV-1 coreceptor [18]. Additional investigations
demonstrated that this interaction and the inhibitory eﬀect
on HIV-1 infection were persistent, providing protection
from infection even after removal of the compound from the
culture medium [19].
The low in vitro cytotoxicity of PEHMB (NB325) sug-
gested that this compound would also be characterized as
safe in a Swiss Webster mouse model used to assess cervicov-
aginaltoxicityassociatedwithcompoundexposure.Previous
studies using this murine model of microbicide toxicity
(i) conﬁrmed the cervicovaginal toxicity and inﬂammation
associated with topical application of nonoxynol-9 (N-9) in
women[20]and(ii)corroborateddiﬀerencesinacceptability
between two diﬀerent formulations of the microbicide API
C31G [21]. In previous mouse model experiments relevant
to the present studies, in vivo exposure to unformulated
1% PEHMB resulted in minimal epithelial damage and
negligible local inﬂammation relative to N-9 and control
mice [20]. These results were consistent with those from in
vitro studies of compound cytotoxicity, which demonstrated
that PEHMB was more than 350-fold less cytotoxic than N-9
[8, 20].
The objectives of the present study were to assess the
safety of NB325 formulated at two concentrations (0.5% and
1%) and to investigate time-dependent eﬀects of application
on cervicovaginal integrity. Experiments were focused on the
acute time points of 10min, 2h, and 4h postapplication,
because these exposure durations were previously shown to
provide important information for gauging acute epithelial
toxicity following N-9 or C31G exposure [20–23]. The
extended time points of 8h and 24h were also included
to provide a full range of observations over a 24h period.
Histological analyses of exposed tissues indicated little to no
toxicity after exposure to 0.5% NB325 and minimal toxicity
after exposure to 1% NB325 for both unformulated and
formulated compound. Interestingly, changes in epithelial
integrity that were observed following exposure to NB325
were noted in the vagina rather than in the cervix, where
N-9 toxicity was readily apparent in previous studies [20].
These studies provide further evidence of the topical safety
of biguanide-based compounds as microbicide APIs.
2.MaterialsandMethods
2.1. Unformulated and Formulated NB325. NB325 was syn-
thesized as previously described for polyhexamethylene
biguanide and PEHMB [8, 18, 24]. The molecular mass of
NB325 ranged from 900 to 1,900Da with a median molecu-
lar mass of approximately 1,400Da. NB325 was determined
to be soluble in water and to exhibit polydispersity. Gel
formulation of NB325 was performed by the International
Partnership for Microbicides using a hydroxyethyl cellulose
(HEC)basedgel,otherwiseknownasthe“universalplacebo”
[25].
2.2. Assessing the In Vivo Eﬀect of Cervicovaginal NB325 Ex-
posure in a Murine Model. These experiments, which were
similar to previously performed studies [20, 21, 23], used
5- to 6-week-old female outbred Swiss Webster mice (CFW)
(Charles River Laboratories, Wilmington, Mass). Prior to
compound or formulation application, the mice were syn-
chronized using a 0.2mL subcutaneous injection of Depo-
Provera (Pharmacia and Upjohn Company, Bridgewater,
NJ) at 7 and 3 days before the start of each experiment.
The Depo-Provera was diluted in Ringer’s lactated saline
solution (Baxter, Deerﬁeld, Ill) to allow administration
of 3mg/animal. Mice were anesthetized with a formula-
tion of ketamine/xylazine (100–200mg/kg and 5–10ng/kg,
respectively) before the intravaginal application of NB325.
Anesthetized animals received an intravaginal inoculation
(60µL) of NB325. Mice treated with saline alone or 1% N-
9 (diluted in saline) were included as controls to evaluate the
morphology of normal or damaged cervicovaginal mucosal
t i s s u e ,r e s p e c t i v e l y .A f t e rt r e a t m e n t ,m i c ew e r es a c r i ﬁ c e d
humanely, and the cervicovaginal tracts were surgically
excised and prepared for histological examination. Each
experiment evaluated 3 animals per time point within each
experimental group.
Mice were sacriﬁced after exposure for 10min, 2h, or
4h and after longer exposures for 8h or 24h. The durationsJournal of Biomedicine and Biotechnology 3
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Figure 1: Exposure to saline results in no damage to the cervicovaginal epithelia. Mice were exposed to saline and sacriﬁced at 10min, 2h,
4h, or 8h after application. H&E-stained vaginal (a) and cervical (b) epithelial tissues were analyzed for damage. Representative micrograph
ﬁelds from the 2h exposure are shown. Images are representative of three mice per exposure duration.
of acute exposure were established previously to characterize
the appearance of epithelial damage following a single
microbicide application [20]. The longer time points were
shown to be useful for characterizing the time course of
epithelial repair and resolution of tissue inﬂammation.
Allexcisedcervicovaginaltissueswereformalin-ﬁxedand
embedded in paraﬃn using previously described procedures
[20, 21, 23]. Paraﬃn-embedded samples were stained with
hematoxylin and eosin (H&E) for gross morphological
analyses,andrepresentativeﬁeldsfromeachtreatmentgroup
were documented in photomicrographs. Tissue toxicity was
assessed observationally across multiple sections.
3. Results
3.1. In Vivo Exposure to Unformulated NB325 Causes Minor
Changes in Cervicovaginal Epithelial Integrity. Although
clinical studies of microbicide safety have included assess-
ments of female reproductive tract health and integrity
following application, these studies were often conducted at
postexposure durations in excess of 24h. As a result, infor-
mation regarding the acute eﬀects of microbicide exposure
has been lacking. Our in vivo studies of N-9 using a mouse
model of cervicovaginal toxicity [20] indicated the need to
include acute and extended exposures in these experiments
in order to observe both short- and long-term eﬀects of
topical application. These results guided the present studies
of NB325 safety.
As controls in these experiments, mice were exposed to
either saline or unformulated N-9 (1%) to provide illustra-
tions of normal or damaged cervicovaginal epithelial tissues,
respectively. Saline exposure for 2h caused no damage to
either the vaginal or the cervical epithelial tissue (Figure 1);
identical results were obtained after exposures of 10min,
4h, 8h, or 24h (data not shown). As in previous studies
[20], N-9 exposure resulted in severe cervical epithelial
shedding and breaks in the epithelia that were greatest at 2h
postexposure (Figure 2(b)) and were still evident at 4h and
8h after N-9 application (Figures 2(d), 2(f)). N-9-associated
cervical damage was resolved by 24h postexposure, as these
tissues were similar in appearance to tissues from saline-
exposed mice (data not shown). The vaginal epithelium was
unaﬀected by N-9 exposure (Figures 2(a), 2(c), 2(e)).
Initial NB325 mouse model studies involved the vaginal
application of unformulated NB325 at concentrations of
0.5% or 1%. At its lower concentration (0.5%), unformu-
lated NB325 caused little or no postexposure cervicovaginal
epithelial damage (data not shown). Although epithelial
cell sloughing and breaks in the epithelium were observed
sporadically in the vagina and cervix, respectively, these
minor indications of toxicity were not apparent by 24h
postexposure (data not shown).
Exposure to 1% unformulated NB325 resulted in a
slightly greater level of toxicity compared to 0.5% NB325.
At 10min postapplication, NB325 exposure resulted in no
damage to the cervicovaginal tract (Figures 3(a), 3(b)). In
the vagina and cervix, the tissue appeared the same as the
placebo control, the vaginal epithelium retained the keratin
layer, the cervix had no cells shed into the lumen, and mucus
production was suggested by the observation that mucus-
producingcellswerepresentintheepitheliallayer.By2hand
4h postapplication, the cervix was still unaﬀected (Figures
3(d),3(f)),whereassometoxicitywasapparentinthevaginal
epithelium (Figures 3(c), 3(e)). At 2h after application, the
vagina began showing signs of toxicity in the form of cells
appearing to loosen from the upper layers of the stratiﬁed
squamous tissue and thinning of the epithelial layer. By 4h
after application, cells were actively shed from the vaginal
epithelium and were present in the lumen. At the extended
exposure durations of 8h and 24h, little to no toxicity was
observed in the vagina (Figures 4(a), 4(c)), although at 24h
some shed tissue was still apparent in the lumen. At 8h
postexposure, the cervical epithelium was generally intact,
withevidenceofasmallnumber ofcellspresentinthelumen
(Figure 4(b)). By 24h postexposure, however, these luminal4 Journal of Biomedicine and Biotechnology
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Figure 2: Exposure to N-9 results in severe damage to cervical epithelial tissues. Mice were exposed to N-9 and sacriﬁced at 10min, 2h,
4h, 8h, or 24h after application. H&E-stained vaginal ((a), (c), (e)) and cervical ((b), (d), (f)) epithelial tissues were analyzed for damage.
Representative micrograph ﬁelds from the 2h, 4h, and 8h exposures are shown. Images are representative of three mice per exposure
duration. Tissues exposed to N-9 for 10min and 24h were similar to saline-exposed tissues (data not shown).
cells were no longer present, and the tissue appeared normal
(Figure 4(d)).
3.2. NB325 Formulation Does Not Impact Its Eﬀe c to nC e r v i -
covaginal Epithelial Integrity. To explore the potential cervi-
covaginal safety of the formulated compound, NB325 was
incorporated into a HEC-based gel, otherwise known as the
universal placebo [25], at ﬁnal concentrations of 0.5% and
1%.Vaginalandcervicalepithelialtissuesfrommiceexposed
to the gel without NB325 (placebo) were indistinguishable
from saline-exposed tissues; there was no observable epithe-
lial damage at any time point (Figure 5 and data not shown).
The eﬀects of exposure to NB325 formulated at 0.5%
were similar to those observed after exposure to unformu-
lated NB325 at the same concentration (data not shown).
In the vagina, indications of minor toxicity were observed
at 8h postexposure in the form of epithelial layer thinning,
indicating that shedding may have occurred at some point
between the 4 h and 8 h time points. By 24h postexposure,Journal of Biomedicine and Biotechnology 5
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Figure 3: Short exposures to 1% unformulated NB325 result in isolated damage to the vaginal epithelium. Mice were exposed to 1%
unformulated NB325 for 10min, 2h, or 4h prior to sacriﬁce and cervicovaginal tissue isolation. H&E-stained vaginal ((a), (c), (e)) and
cervical ((b), (d), (f)) tissue sections were analyzed for epithelial damage. Representative micrograph ﬁelds for each exposure are shown.
Images are representative of three mice per exposure duration.
epithelial damage was no longer apparent; tissues were
similar in appearance to the controls. The cervix appeared to
be unaﬀected by any length of exposure to 0.5% formulated
NB325.
Similar experiments were performed to examine the ef-
fects of a formulation containing a higher concentration
(1%) of NB325. At 10min following application, min-
imal damage to the vagina was observed (Figure 6(a)),
whereas the cervix appeared normal and showed indications
of mucus production (Figure 6(b)). By 2h after application,
signs of toxicity in the vaginal tract were apparent, indicated
by the presence of sloughed cells in the lumen and thinning
of the epithelial layer (Figure 6(c)). At 4h after application,
an increase in vaginal tissue damage relative to the 2-
h exposure was observed (Figure 6(e)). By 8h and 24h
postexposure, however, vaginal epithelia appeared normal,
with no observable residual tissue damage (Figures 7(a),
7(c)). Although cervical epithelial tissues exposed to formu-
lated 1% NB325 were generally intact, some cell inﬁltration
beneath the basal layer of the cervical epithelium was visible6 Journal of Biomedicine and Biotechnology
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Figure 4: Exposure to 1% unformulated NB325 for 8h or 24h is characterized by little or no change in cervicovaginal epithelial integrity.
Mice were exposed to 1% unformulated NB325 for 8h or 24h prior to sacriﬁce and cervicovaginal tissue isolation. H&E-stained tissue
sectionswereanalyzedfordamagetothevaginal((a),(c))andcervical((b),(d))epithelia.Representativemicrographﬁeldsforeachexposure
are shown. Images are representative of three mice per exposure duration.
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Figure 5: Application of gel only (placebo) causes no damage to the cervicovaginal epithelium. Mice were exposed to the HEC-based
formulation placebo and sacriﬁced after application for 10min, 2h, 4h, or 8h. Vaginal (a) and cervical epithelial tissues (b) were
subsequently isolated and analyzed for damage. Representative micrograph ﬁelds from the 2h exposure are shown. Images are representative
of three mice per exposure duration.Journal of Biomedicine and Biotechnology 7
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Figure 6: Short exposures to NB325 formulated at 1% result in mild vaginal epithelial toxicity. Mice were exposed to 1% formulated NB325
for 10min, 2h, or 4h prior to sacriﬁce and isolation of reproductive tract tissues. H&E-stained tissue sections were analyzed for toxicity
to the vaginal ((a), (c), (e)) and cervical ((b), (d), (f)) epithelia. Representative micrograph ﬁelds for each exposure are shown. Images are
representative of three mice per exposure duration.
at2hand4hpostexposure(Figures6(d),6(f)).Interestingly,
the sporadic appearance of mild cervical epithelial damage
was noted at 8h after application (Figure 7(b)). This damage
was characterized by a “loose” appearance of cells along the
epithelial layer, suggesting the presence of epithelial cells
in the process of shedding. At 24h, however, the cervix
appeared normal and intact (Figure 7(d)).
4. Discussion
The vaginal and cervical epithelia within the female repro-
ductive tract provide physical barriers that impede pathogen
access and play host to cells that mount immunologic
responses to those pathogens. The integrity of this physical
and immunologic barrier is crucial to maintaining the health8 Journal of Biomedicine and Biotechnology
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Figure 7: Cervicovaginal epithelial integrity after exposure to 1% formulated NB325 for 8h or 24h is similar to that of controls. Mice were
e x p o s e dt o1 %f o r m u l a t e dN B 3 2 5f o r8ho r2 4hp r i o rt os a c r i ﬁ c ea n di s o l a tion of reproductive tract tissues. H&E-stained tissue sections
were analyzed for toxicity to the vaginal ((a), (c)) and cervical ((b), (d)) epithelia. Representative micrograph ﬁelds for each exposure are
shown. Images are representative of three mice per exposure duration.
of the cervicovaginal environment; disruption of this barrier
could result in an increased risk of infection by sexually
transmitted disease pathogens. With regard to HIV-1, breaks
in these natural barriers can provide a direct route that the
virus can take to reach susceptible cells and establish infec-
tion. Thus, assessment of cervicovaginal epithelial integrity
following exposure to a candidate microbicide is an impor-
tant part of demonstrating the safety of a topical vaginal
formulation and its API. However, a complete evaluation of
in vivo safety must also encompass other approaches, such
as investigations of inﬂammatory cell inﬁltration [20, 21],
assays of cytokine expression and release, and experiments
todemonstrateincreasedsusceptibilitytoinfectionfollowing
topical microbicide exposure [26].
Thepresentmousemodelstudies,whichwereperformed
to provide an initial evaluation of formulated NB325 safety,
oﬀer the basis for several conclusions. First, the results
of experiments involving unformulated NB325 suggest a
much greater level of safety relative to N-9, which has been
shown in these and other studies to cause severe damage
to cervicovaginal epithelial tissues. These studies corrob-
orate and expand on previous results that demonstrated
the minimal eﬀect of unformulated PEHMB on epithelial
integrity and the absence of CD45-positive immune cell
inﬁltration following exposure [20]. The present studies in-
dicate a similar level of safety for unformulated NB325,
which was produced through the application of reﬁnements
to the synthetic methods used to produce PEHMB [17, 18].
Second, these results also indicate a relative level of in
vivo safety for NB325 formulated in an HEC-based gel. The
eﬀects of formulated NB325 on vaginal epithelial integrity
are in sharp contrast to the severe and widespread cervical
epithelial damage and tissue sloughing (as well as induction
of immune cell inﬁltration) caused by the application of
unformulated and formulated N-9 (Conceptrol) [20]. In
fact, the results of mouse experiments involving formulated
NB325 are comparable to the results of similar experiments
using 1% formulated C31G [21], which was shown in several
independent clinical trials (as the topical agent SAVVY)
to be safe and acceptable for human application [27–29].
However, because the 1% formulated NB325 appeared to
be slightly more toxic in vivo relative to the formulation
containing 0.5% NB325, the concentration of NB325 in
future microbicide formulations will need to be considered
further.
The indication of concentration-dependent eﬀects on
epithelial integrity also hints at the bioavailability of
NB325 in the HEC-based formulation. Although NB325Journal of Biomedicine and Biotechnology 9
bioavail-ability was not addressed in the present studies,
preliminary experiments involving HIV-1 infection of indi-
cator cells in the presence of formulated NB325 indeed
demonstrated antiviral activity attributable to NB325 (data
not shown). However, the antiviral activity of NB325 in this
transwell-based experimental system was partly obscured by
the barrier eﬀect of the viscous HEC-based gel, indicating a
limitationofthismethodformeasuringdrugavailabilityand
biological activity and the need for additional investigations
in this direction.
The third conclusion concerns the location of the rela-
tively limited epithelial damage caused by unformulated and
formulated NB325. When epithelial damage was observed as
a consequence of NB325 exposure, it was found predomi-
nantly in the vagina and observed infrequently in the cervix.
In contrast, previous investigations demonstrated that the
severe epithelial damage caused by N-9 was conﬁned to the
cervix; the vaginal epithelium appeared to be resistant to
any damage caused by a single application of N-9 [17, 20].
Similarly, losses in epithelial integrity associated with C31G
exposure were found exclusively in the cervix [21].
These diﬀerences may be related both to the chemical
nature of each compound and the respective microenvi-
ronments of the vagina and cervix. NB325 is an aqueous,
nonsurfactant compound with a net positive charge at phys-
iological pH, whereas N-9 and C31G are both surfactants.
Within the cervix, mucus released from the epithelial surface
mayinteractwithNB325andprotectthecolumnarepithelial
cells from any toxicity associated with NB325. This layer of
cervical mucus may not aﬀord the same protection against
surfactants such as N-9 or C31G. Conversely, the absence
of mucus in the vagina may leave the vaginal epithelium
vulnerable to the potential eﬀects of NB325. However, the
structure of the stratiﬁed squamous epithelium in the vagina
may be more impervious to the surfactant properties of N-
9 or C31G. The present studies and results (i) stress the
importanceofconsideringcervicovaginalenvironmentalfac-
tors in designing and evaluating candidate microbicides and
(ii) highlight the potential impact of API and formulation
chemistry on microbicide safety.
Compound chemistry may also be highly relevant to
topical vaginal microbicide clinical eﬃcacy. Microbicides
shown to be safe but ineﬀective in clinical trials (Ushercell,
Carraguard, and PRO2000) may have failed due to elec-
trostatic interactions between their polyanionic APIs and
charged seminal plasma components that interfere with their
antiviral activities [30, 31]. Because NB325 is polycationic,
its antiviral activity should be unaltered in the presence of
semen. Indeed, cationic peptides endogenous to semen have
been shown to provide an inherent antiviral activity against
HIV-1[32].Theeﬀectsofbothmaleandfemalereproductive
tractsecretionsonNB325activitywillbeaddressedaspartof
the preclinical development of this compound.
5. Conclusions
In vivo experiments involving a mouse model of cervicov-
aginaltoxicityprovidesupportforthesafeuseofagelformu-
lation containing the biguanide-based antiviral compound
NB325asatopicalvaginalmicrobicide.However,indications
of minor dose-dependent eﬀects on epithelial integrity
and regional diﬀerences in the eﬀects of NB325 on the
cervicovaginal tract indicate the need for further preclinical
studies to arrive at an optimal API concentration and
formulation.
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